参考文献/References:
[1] 孙莹莹,孙夕林,王凯,等.EGFR靶向的PET/SPECT分子成像研究进展[J].现代生物医学进展,2014,14(10):1980-1986.
[2] Laskin JJ,sandier AB.Eoidermal growth factor receotor:a promising target in solid tumours[J/OL].Cancer Treat Rev,2004,30(1):1-17[2014-11-09].http://www.sciencedirect.com/sci-ence/article/pii/S0305737203002020.
[3] Eccles SA.Cell biology of lymphatic metastasis.The potential role of c-erbB oncogene signalling[J].Recent Results Cancer Res,2000,157:41-54.
[4] Shepherd FA,Pereira JR,Ciuleanu T,et al.Erlotinib in previously treated non-small-cell lung cancer[J].N Engl J Med,2005,353(2):123-132.
[5] Madhusudan S,Ganesan TS.Tyrosine kinase inhibitors in cancer therapy[J/OL].Clin Biochem,2004,37(7):618-635[2014-11-01],http://www.sciencedirect.com/science/article/pii/S0009912004001298.
[6] Schiller JH.Noninvasive monitoring of tumors[J/OL].N Engl J Med,2008,359(4):418-420[2014-11-01].http://connec-tion.ebscohost.com/c/editorials/33291815/noninvasive-monitoring-tumors.
[7] Levitzki A.Protein kinase inhibitors as a therapeutic modality[J].Acc Chem Res,2003,36(6):462-469.
[8] Reilly RM,Kiarash R,Cameron RG,et al.111In-labeled EGF is se-lectively radiotoxic to human breast cancer cells overexpressing EGFR[J].J Nucl Med,2000,41(3):429-438.
[9] Reilly RM,Kiarash R,Cameron RG,et al.A comparison of EGF and Mab 528 labeled with 111In for imaging human breast cancer[J].J Nucl Med,2000,41(5):903-911.
[10] Jung KH,Park J W,Paik JY,et al.EGF receptor targeted tumorimaging with biotin-PEG-EGF linked to 99mTc-HYNIC labeledavidin and streptavidin[J].Nucl Med Biol,2012,39(8):1122-1127.
[11] Jung KH,Choe YS,Paik JY,et al.99mTc-Hydrazinonicotinamide epidermal growth factor-polyethylene glycol-quantum dot imagingallows quantification of breast cancer epidermal growth factor re-ceptor expression and monitors receptor downregulation in response to cetuximab therapy[J].J Nucl Med,2011,52(9):1457-1464.
[12] 戴春岭,符立梧.靶点药物Cetuximab(C225)研究新进展[J].生物化学与生物物理进展,2007,34(3):246-254.
[13] Schechter NR,Yang DJ,Azhdarinia A,et al.Assessment of epider-mal growth factor receptor with 99mTc-ethylenedicysteine-C225 monoclonal antibody[J].Anticancer Drugs,2003,14(1):49-56.
[14] Liu Z,Ma T,Liu H,et al.177Lu-labeled antibodies for EGFR-target-ed SPECT/CT imaging and radioimmunotherapy in a preclinical head and neck carcinoma model[J].Mol Pharm,2014,11(3):800-807.
[15] Xu N,Cai G,Ye W,et al.Molecular imaging application of radioio-dinated anti-EGFR human Fab to EGFR-overexpressing tumor xenografts[J].Anticancer Res,2009,29(10):4005-4011.
[16] Wang X,Zhu J,Zhao P,et al.In vitro efficacy of immuno-chemotherapy with anti-EGFR human fab-taxol conjugate on A431 epidermoid carcinoma cells[J].Cancer Biol Ther,2007,6(6):980-986.
[17] 董强刚,李建璋,黎飒,等.上皮生长因子受体外显子21基因突变L858R的实时定量PCR检测[J].肿瘤,2007,27(2):150-154.
[18] Pal A,Balatoni JA,Mukhopadhyay U,et al.Radiosynthesis and ini-tial in vitro evaluation of[18F] F-PEG6-IPQA——a novel PET radio-tracer for imaging E GFR expression-activity in lung carcinomas[J].Mol Imaging Biol,2011,13(5):853-861.
[19] Yeh HH,Ogawa K,Balatoni J,et al.Molecular imaging of active mutant L858R EG F receptor (EgFR) kinase-expressing nonsmall cell lung carcinomas using PET/CT[J].Proc Natl Acad Sci USA.2011,108(4):1603-1608.
[20] Pal A,Glekas A,Doubrovin M,et al.Molecular imaging of EGFR kinase activity in tumors with 124I-labeled small molecular tracer and positron emission tomography[J].Mol Imaging Biol,2006,8(5):262-277.
[21] Wong SF.Cetuximab:an epidermal growth factor receptor mono-clonal antibody for the treatment of colorectal cancer[J].Clin Ther,2005,27(6):684-694.
[22] Cai W,Chen K,He L,et al.Quantitative PET of EGFR expression in xenograft-bearing mice using 64Cu-labeled cetuximab,a chimeric anti-EGFR monoclonal antibody[J].Eur J Nucl Med Mol Imaging,2007,34(6):850-858.
[23] Sadri K,Ren Q,Zhang K,et al.PET imaging of EGFR expression in nude mice bearing MDA-MB-468,a human breast adenocarcino-ma[J].Nucl Med Commun,2011,32(7):563-569.
[24] Eiblmaier M,Meyer LA,Watson MA,et al.Correlating E GFR ex-pression with receptor-binding properties and internalization of 64Cu-DOTA-cetuximab in 5 cervical cancer cell lines[J].J Nucl Med,2008,49(9):1472-1479.
[25] Niu G,Sun XL,Cao QZ,et al.Cetuximab-Based immunotherapy and radioimmunotherapy of head and neck squamous cell carcinoma[J].Clin Cancer Res,2010,16(7):2095-2105.
[26] Perk LR,Visser GW,Vosjan MJ,et al.89Zr as a PET surrogate ra-dioisotope for scouting biodistribution of the therapeutic radiometals and 177Lu in tumor-bearing nude mice after coupling to the internalizing antibody cetuximab[J].J Nucl Med,2005,46(11):1898-1906.
[27] Aerts HJ,Dubois L,Perk L,et al.Disparity between in vivo EGFR expression and 89Zr-labeled cetuximab uptake assessed with PET[J].JNucl Med,2009,50(1):123-131.
[28] Miao Z,Ren G,Liu H,et al.PET of E GFR expression with an 18F-labeled affibody molecule[J].J Nucl Med,2012,53(7):1110-1118.
[29] Fredriksson A,Johnstrom P,Thorell JO,et al.In vivo evaluation of the biodistribution of 11C-labeled PD153035 in rats without and with neuroblastoma implants[J].Life Sci,1999,65(2):165-174.
[30] Meng X,Loo BW,Ma L,et al.Molecular imaging with 11C-PD153035 PET/CT predicts survival in non-small cell lung cancer treated with EGFR-TKI:a pilot study[J].J Nucl Med,2011,52(10):1573-1579.
[31] Memon AA,Jakobsen S,Dagnaes-Hansen F,et al.Positron emis-sion tomography (PET) imaging with[11C]-labeled erlotinib:a micro-PET study on mice with lung tumor xenografts[J].Cancer Res,2009,69(3):873-878.
[32] Memon AA,Weber B,Winterdahl M,et al.PET imaging of patients with non-small cell lung cancer employing an EGF receptor target-ing drug as tracer[J].Br J Cancer,2011,105(12):1850-1855.
[33] Holt DP,Ravert HT,Dannals RF,et al.Synthesis of [11C]gefitinib for imaging epidermal growth factor receptor tyrosine kinase with positron emission tomography[J/OL].J label compd Radiopharm,2006,49(10):883-888[2014-11-8].http://onlinelibrary.wi-ley.com/doi/10.1002/jlcr.1104/abstract.
[34] Zhang MR,Kumata K,Hatori A,et al.[11C]Gefitinib ([11C]Iressa):radiosynthesis,in vitro uptake,and in vivo imaging of intact murine fibrosarcoma[J].Mol Imaging Biology,2010,12(2):181-191.
[35] Murali D,Flores Lg.Evaluation of[F-18] iressa as a PET imaging agent for tumor overexpressing epidermal growth factor (EGFR) re-ceptors[J/OL].J Label Compd Radiopharm,2005,48(S1):S1-S341[2014-11-09].http://onlinelibrary.wiley.com/doi/10.1002/jlcr.v48:1%2B/issuetoc.
[36] Seimbille Y,Phelps ME,Czernin J,et al.Fluorine-18 labeling of 6,7-disubstituted anilinoquinazoline derivatives for positron emission tomography (PET) imaging of tyrosine kinase receptors:synthe-sis of 18F-Iressa and related molecular probes[J/OL].J Label Compd Radiopharm,2005,48(11):829-843[2014-11-01].http://onlinelibrary.wiley.com/doi/10.1002/jlcr.998/abstract.
[37] Su H,Seimbille Y,Ferl GZ,et al.Evaluation of [18F]gefitinib as a molecular imaging probe for the assessment of the epidermal growth factor receptor status in malignant tumors[J].Eur J Nucl Med Mol Imaging,2008,35(6):1089-1099.
[38] Bonasera TA,Ortu G,Rozen Y,et al.Potential 18F-labeled biomark-ers for epidermal growth factor receptor tyrosine kinase[J].Nucl Med Biol,2001,28(4):359-374.
[39] Ortu G,Ben-David I,Rozen Y,et al.Labeled EGFr-TK irreversible inhibitor(ML03):in vitro and in vivo properties,potential as PET biomarker for cancer and feasibility as anticancer drug[J].Int J Cancer,2002,101(4):360-370.
[40] Tsou HR,Mamuya N,Johnson BD,et al.6-Substituted-4-(3-bro-mophenylamino) quinazolines as putative irreversible inhibitors of the epidermal growth factor receptor (EGFR) and human epider-mal growth factor receptor(HER-2) tyrosine kinases with enhanced antitumor activity[J].J Med Chem,2001,44(17):2719-2734.
[41] Mishani E,Abourbeh G,Rozen Y,et al.Novel carbon-11 labeled 4-dimethylamino-but-2-enoic acid[4-(phenylamino)-quinazoline-6-yl]-amides:potential PET bioprobes for molecular imaging of EGFR-positive tumors[J].Nucl Med Biol,2004,31(4):469-476.
[42] Dissoki S,Laky D,Mishani E,et al.Fluorine-18 labeling of ML04-presently the most promising irreversible inhibitor candidate for vi-sulization of E GFR in cancer[J/OL].J Label Compd Radiopharm,2006,49(6):533-543[2014-11-9].http://onlinelibrary.wiley.com/doi/10.1002/jlcr.1071/abstract.
[43] Abourbeh G,Dissoki S,Jacobson O,et al.Evaluation of radiola-beled ML04,a putative irreversible inhibitor of epidermal growth factor receptor,as a bioprobe for PET imaging of EGFR-overex-pressing tumors[J].Nucl Med Biol,2007,34(1):55-70.
[44] Shaul M,Abourbeh G,Jacobson O,et al.Novel iodine-124 labeled EGFR inhibitors as potential PET agents for molecular imaging in cancer[J].Bioorg Med Chem,2004,12(13):3421-3429.
[45] Solca F,Dahl G,Zoephel A,et al.Target binding properties and cellular activity of afatinib (BIBW 2992),an irreversible ErbB family blocker[J].J Pharmacol Exp Ther,2012,343(2):342-350.
[46] Slobbe P,Windhorst AM.Development of [18F]afatinib as a new TKI-PET tracer for EGFR positive tumors[J].Nucl Med Biol,2014,41(9):749-757.
[47] Fernandes C,Oliveira C,Gano L,et al.Radioiodination of new EGFR inhibitors as potential SPECT agents for molecular imaging of breast cancer[J].Bioorg Med Chem,2007,15(12):3974-3980.
[48] Neto C,Fernandes C,Oliveira MC,et al.Radiohalogenated 4-anili-noquinazoline-based EGFR-TK inhibitors as potential cancer imag-ing agents[J].Nucl Med Biol,2012,39(2):247-260.
[49] Bourkoula A,Paravatou-Petsotas M,Papadopoulos A,et al.Synthe-sis and characterization of Rhenium and technetium-99m tricar-bonyl complexes bearing the 4-[3-bromophenyl] quinazoline moi-ety as a biomarker for EGFR-TK imaging[J].Eur J Med Chem,2009,44(10):4021-4027.
[50] Hirata M,Kanai Y,Naka S,et al.Evaluation fo radioiodinated quinazoline derivative as a new ligand for EGF receptor tyrosine ki-nase activity using SPECT[J].Ann Nucl Med,2011,25(2):117-124.
[51] Hirata M,Kanai Y,Naka S,et al.Synthesis and evaluation of ra-dioiodinated phenoxyquinazoline and benzylaminoquinazoline derivatives as new EGF receptor tyrosine kinase imaging ligands fortumor diagnosis using SPECT[J].Ann Nucl Med,2012,26(5):381-389.
[52] Hirata M,Kanai Y,Naka S,et al.A useful EGFR-TK ligand for tu-mor diagnosis with SPECT:development of radioiodinated 6-(3-morpholinopropoxy)-7-ethoxy-4-(3’-iodophenoxy) quinazoline[J].Ann Nucl Med,2013,27(5):431-443.
[53] Cai W,Niu G,Chen X.Multimodality imaging of the HER-kinase axis in cancer[J].Eur J Nucl Med Mol Imaging,2008,35(1):186-208.
相似文献/References:
[1]周玉祥,蓝博文,黄春榆,等.64排螺旋CT冠状动脉血管成像诊断冠状动脉-肺动脉瘘的应用价值[J].国际放射医学核医学杂志,2016,40(1):26.[doi:10.3760/cma.j.issn.1673-4114.2016.01.006]
Zhou Yuxiang,Lan Bowen,Huang Chunyu,et al.Clinical value of coronary artery-pulmonary artery fistula revealed by 64-slice spiral CT coronary angiography[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(1):26.[doi:10.3760/cma.j.issn.1673-4114.2016.01.006]
[2]陈超坤,刘亮,傅飞先,等.囊性胸腺瘤和囊性畸胎瘤的影像学特征及鉴别诊断[J].国际放射医学核医学杂志,2016,40(1):31.[doi:10.3760/cma.j.issn.1673-4114.2016.01.007]
Chen Chaokun,Liu Liang,Fu Feixian,et al.Imaging features and differential diagnosis of cystic thymoma and cystic teratoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(1):31.[doi:10.3760/cma.j.issn.1673-4114.2016.01.007]
[3]岳进,苏丽萍.全身MRI与PET/CT在淋巴瘤骨髓浸润诊断及预后中的作用[J].国际放射医学核医学杂志,2016,40(1):50.[doi:10.3760/cma.j.issn.1673-4114.2016.01.010]
Yue Jin,Su Lipin.Function of whole-body MRI and PET/CT in the diagnosis and prognosis of lymphoma with bone marrow infiltration[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(1):50.[doi:10.3760/cma.j.issn.1673-4114.2016.01.010]
[4]张莹莹,王振光,孔艳.PET/CT显像在肺间质纤维化中的应用进展[J].国际放射医学核医学杂志,2016,40(1):55.[doi:10.3760/cma.j.issn.1673-4114.2016.01.011]
Zhang Yingying,Wang Zhenguang,Kong Yan.Application advancement on PET/CT in pulmonary interstitial fibrosis[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(1):55.[doi:10.3760/cma.j.issn.1673-4114.2016.01.011]
[5]麦卫平,张永林.能谱CT成像在肺癌诊断中的应用研究进展[J].国际放射医学核医学杂志,2016,40(1):77.[doi:10.3760/cma.j.issn.1673-4114.2016.01.015]
Mai Weiping,Zhang Yonglin.Research progress of spectral imaging in the diagnosis of lung cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(1):77.[doi:10.3760/cma.j.issn.1673-4114.2016.01.015]
[6]史文杰,孟召伟,谭建.基于Deauville标准探讨18F-FDG PET/CT在霍奇金淋巴瘤复发诊断中的应用价值[J].国际放射医学核医学杂志,2016,40(2):120.[doi:10.3760/cma.j.issn.1673-4114.2016.02.007]
Shi Wenjie,Meng Zhaowei,Tan Jian.Value of 18F-FDG PET/CT on diagnosis of Hodgkin lymphoma recurrence using Deauville criterion[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(1):120.[doi:10.3760/cma.j.issn.1673-4114.2016.02.007]
[7]周翠屏,廖俊杰,何国华,等.原发性肠系膜巨大淋巴结增生症的MSCT表现与病理对照分析[J].国际放射医学核医学杂志,2016,40(3):175.[doi:10.3760/cma.j.issn.1673-4114.2016.03.003]
Zhou Cuiping,Liao Junjie,He Guohua,et al.Primary mesenteric Castleman disease:MSCT findings with histopathologic correlation[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(1):175.[doi:10.3760/cma.j.issn.1673-4114.2016.03.003]
[8]张巧娜,刘汉东.上颌窦上皮-肌上皮癌的CT表现一例[J].国际放射医学核医学杂志,2016,40(3):237.[doi:10.3760/cma.j.issn.1673-4114.2016.03.015]
[9]尤阳,轩昂,张杰,等.淋巴瘤患者大脑静息葡萄糖代谢改变[J].国际放射医学核医学杂志,2016,40(4):255.[doi:10.3760/cma.j.issn.1673-4114.2016.04.003]
You Yang,Xuan Ang,Zhang Jie,et al.Changes in resting-state brain glucose metabolism in patients with lymphoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(1):255.[doi:10.3760/cma.j.issn.1673-4114.2016.04.003]
[10]王朋,崔邦平,代文莉,等.18F-FDG PET/CT在前列腺癌中的应用进展[J].国际放射医学核医学杂志,2016,40(4):277.[doi:10.3760/cma.j.issn.1673-4114.2016.04.008]
Wang Peng,Cui Bangping,Dai Wenli,et al.Progress in the application of 18F-FDG PET/CT in prostate cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(1):277.[doi:10.3760/cma.j.issn.1673-4114.2016.04.008]